[ Licensing ]
Licensing
PolyMedix seeks partners throughout the world for a number of our products. The preferred partnering strategy may vary depending on the compound, target indication(s), stage of development and geographic markets. Below is a description of PolyMedix compounds we are interested in partnering, particularly in the areas indicated.
| Product | Stage | Indication | Partners Sought |
PMX-30063
Small molecule mimetics of host defense proteins
| Preclinical development | - Antibacterial
- Antifungal
- Antiviral
| Global or Regional |
PMX-60056
Heptagonists
| Preclinical development | - Reverse action of heparin, LMWH and pentasaccharide
| Global or regional |
PMX-50003, PMX-70004
Polymer mimetics of host defense proteins
| Proof of concept | | Global or regional |
| Transmembrane protein receptor crystallization of partner's protein target | Research | | Global |
PMX-20005
Small molecule angiogenesis inhibitor
| Research | - AMD (Age related Macular Degeneration)
- Cancer
| Global or regional |
To inquire about any of our out-licensing opportunities, please contact:
Dawn Eringis
Vice President, Business Development
PolyMedix, Inc.
170 N. Radnor-Chester Road
Suite 300
Radnor, PA 19087
USA
Phone:+1- 610-613-0621
Email: deringis@polymedix.com
return to top ^ |
